Patent · US Active

Modulation of huntingtin expression

US8906873B2 · kind B2 · utility

6Cited by

9References

8Claims

0Family size

Assignee

Isis Pharmaceuticals, Inc. · US

Inventors

Gene Hung · San Francisco, US
C. Frank Bennett · Carlsbad, US
Susan M. Freier · San Diego, US
Holly Kordasiewicz · San Diego, US
Lisa Stanek · Natick, US
Don W. Cleveland · Alameda, US
Seng H. Cheng · Wellesley, US
Lamya Shihabuddin · Watertown, US

Key dates

Filing date	Sep 10, 2010
Grant date	Dec 9, 2014
Priority date	—
Expiry date	Sep 10, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/346
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.